Post-Transplants Infections: A Brief Review
Fakhriya Alalawi1,2*, Mohsen El Kosi2,3, Jon Kim Jin2,4, Ajay Sharma2,5, Ahmed Halawa2,6
1Department
of Nephrology, Dubai Hospital, Dubai Health Authority.Dubai, UAE
2University
of Liverpool, Institute of Learning and Teaching, School of Medicine,
Liverpool,UK
3Doncaster
Royal Infirmary, Doncaster, UK
4Nottingham
Children Hospital, Nottingham, UK
5Royal Liverpool University Hospital, Liverpool, UK
6Sheffield Teaching Hospitals, Herries Road, Sheffield-United Kingdom
*Corresponding author: FakhriyaAlalawi, Faculty of Health and Science, University of Liverpool, Institute of Learning and Teaching, School of Medicine, Liverpool - United Kingdom. Tel:00971509787597, 0097402195000;E-mail: fjalalawi08@yahoo.co.uk
Received Date:14June, 2017; Accepted
Date: 31July, 2017; Published Date: 07 August, 2017
Citation: Alalawi F, Kosi ME, Jin JK, Sharma A, Halawa A (2017) Post-Transplants Infections: A Brief Review.J Urol Ren Dis 2017: 139. DOI: 10.29011/2575-7903.000139
1. Abstract
Organs transplant had carried a great hope to patients with end organs damage;nevertheless, with the great advancement in the therapeutics and with the institution of new and strong immunosuppressive medications, the acute rejection rate had declined significantly over past decadesparticularly at the first-yearpost-transplant.Butthe consumption of these potent immunosuppressive agents had led to appearances ofseveral opportunistic infections such as cytomegalovirus, Epstein-Barr virus (EBV), BK, parasiticand fungal infectionswhich had emerged extensively. Moreover, the rate of new cancers had increased extensively, owed to the oncogenic influences of these agents.
2.
Keywords:BK; Chagas Disease;
CMV; EBV; Fungal Infections; HBV; HCV; Transplant Recipients; Tuberculosis
1. General Background
Infection is the principal cause of morbidity and mortality in transplant populace. It is a great challenge to identify post-transplant infection at early stage, owed to suppressed immunity level which makesthe characteristic signs and symptoms of infection such as fever, rigors and others are unusual till advanced disease; hence an early diagnosis with specific institution of antimicrobial therapy is crucial.Moreover, utilization of special tests including certain invasive diagnostic techniques is often mandatory to reach an accurate diagnosis in prompt timing[1,2].
2. Risk of Infection
Clinicians have to balance between the risks of infection owed to immunosuppressant medication versus the risk for acute rejection. Unfortunately, there is no concurrent single assay that can predict patient susceptibility to infection, hence the use of prophylactic therapy is based on patient’s history, lab results and the susceptibility of each individualto get the infection.
2.1. Epidemiological Exposure:couldcategorizein to 4groups: donors-related, recipients-related, nosocomial, and community-acquired infections[1].
2.2. Donor-related Infections: certain infectionssuch as tuberculosis, CMV, and T. cruzican remained dormant inside the donor cells and transmitted thereafter to the recipient, hence pre-transplantorgans screening for such infections is essential.Moreover, bacteraemia or viremia can be easily missed at the time of organs procurement leading to invasive recipient’s dissemination. Additionally, more unusual infections have been transmitted from the deceased donors and were reported, including rabies, HIV, choriomeningitis virus andWest Nile viral infection.The prognosis of transplant recipients with such disseminated infections are poor owed to depressed immunity level, leading to rapid disease progression, permanent neurological sequels and death.Unfortunately, screening of transplanted organs for such infection is constrained by the current techniques and by the brief time frame amid which organs from deceased donors can be utilized.Conversely and for special circumstances, organs from donors with certain determined pathogensmight be accepted for particular recipients with well explained situation and recipientagreement, depending on the insistence of the transplantbesidesaccessibility of related treatments.For instances; organs from hepatitis B virus infected donors with positive anti-HB core Ag are presently transplanted to fewpatients who had received the vaccines or were infected earlier with the virus, providing availability of HBV antiviral therapy. Utilization of HCV infected organ is debatable and should be held in reserve (if needed) for infected HCV individuals. It is advisable to evade using organs from infected deceased donors with encephalitis, rash, unexplained fever or untreated infections[1,2].
2.3. Recipient-related Infections:The impacts of donor-related or recipient-related infections such as Tuberculosis are strongly seen in the endemic regions. Any acute and current infective process affecting potential candidates must be treated prior to transplant surgery to avoid any disseminated infection post-transplant owed to suppressed immunity[1,2].
2.4. Nosocomial Infection:Patients may get nosocomial, antimicrobial resistant pathogens while they are waiting to get transplanted.Such pathogens as MRSA, vancomycinres. enterococcus, Clostridium difficile, azole-resistant candida, aspergillus, can grow aggressively at post-transplant period causing different clinical profiles, ranging from mild infection of the wound, and catheters to severe fulminant infection such as severe pneumonia or sepsis.
2.5. Community
acquired Infections:simple and undetected infections in the normal individuals may
cause catastrophic infection in the transplant recipients, such as nocardia, aspergillus, C. neoformans, and
respiratory viral infection[1,3].
3. Immunosuppression Net Status
Immunosuppression
net status denotes all causes which add to patient’s risk of having infections.
Main risk factors include type, dosage and overall period of immunosuppression.Immunosuppressant’s
levels are the measurement frequently practiced to monitor therapy with an aim
to balance between the risk of graft rejection and side effects of
medications.However, such measurements are considered as old and crude methods
which need to be replaced ultimately with sensitive assays to allow patient
individualization and probably minimization of immunosuppression [1].
3.1. Timeline of common infectious pathogens in transplant recipients
Infectivepathogenscan frequently be distinguished on the
premise of the time interim from transplantation to clinical presentation. For
instance, overwhelmed infections at the first month post-transplantation
usually related to surgical procedures, including urinary tract infection (mainly
with E.coli), wound and vascular line
infection and pneumonia, while the following 1-6 months have excessive risk of
viral and opportunistic diseases, related to the increased immunosuppressive
dosages.Thereafter the risk of infection reduces significantly with
subsequent reduction of immunosuppressant’s medications.Nonetheless, transplant
recipients still at persistent risk of community acquired infections in
addition to chronic viral infections such as HCV and CMV as well as
opportunistic pathogens.Severe infections with unusual organisms suggests over
immunosuppression or exposure, particularly following acute rejection or
escalation of immunosuppressant’s therapy[1-5] (Figure
1).
3.2. Common
Infections in Transplant recipients
Prompt
diagnosis is crucial in immunocompromised patients, often requires invasive
diagnostic methods.The most diagnosed infectious
pathogens are bacteria (in 45.9%), viruses (40.6%), fungi (12.5%), and protozoa
(1%).The most well-known viruses are CMV in 31.5%, HSV 23.4%, and
varicella-zoster virus in 23.4% (2,6).
Incisional wound infections is not uncommon, and the most often isolated
pathogens are E.coli, Pseudomonas, Enterococcus faecalis, Enterobacter,
staphylococcus aureus and coagulase-negative staphylococci . Risk factors were diabetes and sirolimus therapy.
Surgical wound infection requires early debridement combined with antibiotics,
organ involvement or adjacent cavities need to be excluded [6].Moreover, kidney and pancreatic recipients mighthavelymphoceles,
peri-graft hematomasand urinary fistula complicating surgery.Liver recipients
might have complicated intra-abdominal infections such as intra-abdominal
abscesses, hepatic abscess,biliary infections (leakage, stricture), hepatic
artery thrombosis, internal bleedings and peritonitis, these infections mainly caused
with bacterial organisms(in 50% of the cases) and can leads to significant
morbidity and mortality [5,7].Heart recipients
are at risk of acquiring mediastinitis and infections at aortic suture lines,
resulting in mycotic aneurysms, while lung recipients might develop
disturbanceat bronchial anastomosis. The frequentlyelaboratedpathogens are
staphylococcus and gram-negative bacteria’s. Treatment involveswound debridementand
antimicrobial therapy for 3 to 6 weeks [5].
5. Gastrointestinal Infections
Gastrointestinal complaints are frequently reported in transplant recipients (in 51 to 68%)ranging from mild to severe, 15% of those might necessitateradiological, endoscopic examination or even surgical exploration[8,9].Abdominal pain is commonly reported complaint in 20-61% of the cases, followed by dyspepsia (52%), diarrhoea (40-51%) and nausea (34%). CMV and C.difficile are the frequently recognized organisms in the pathogenesis of infectious post-transplant diarrhoea.However, if diarrhoea persisted despite excluding those, then more extensive and sophisticated approaches ought to be considered.There are several reported cases withunusual pathogens suchas rotaviruses, enteroviruses, adenoviruses, EBV, Cryptosporidium and others.Other differential diagnoses of post-transplant diarrhoeaconsist of intestinal ischemia, diverticulitis, malignancy,inflammatory bowel disease (whether de-novo or a flare up of pre-existing disease) and PTLD[5,10,11].
C. Difficile Associated Diarrhoea (CDAD) can be suspected in transplant recipients with frequent hospital admissions, prolonged antibiotics courses and with intense immunosuppression.Clinically it might present with severe diarrhoea (absence of diarrhoeacarries poor prognosis) and leucocytosis that can be the only diagnostic clue.Rarely patients can have acute abdomen or inflammatory pseudotumor.Diagnosis is through analysis of fresh stool samples for the presence of C. difficiletoxins. Additionally, the organisms can be proven on rectal swabs.Management is by cessation of the antibiotic therapy when possible. Patients with severe diarrhoea can be treated with oral vancomycin with or without IV metronidazole.10-25% of the CDAD responders might have a relapse (within 3 to10 days following discontinuation of therapy) and they do respond to another systemic antibioticcourse [10-15]. Alternatively, immunosuppressant’ssuch as MMF, cyclosporine, tacrolimus and sirolimus are altogether known to cause diarrhoea.A systematic approach ought to be followed before deciding any dose reduction [5,16].Regardless the cause, diarrhoeais related to inferior renal allograft outcomes and can escalate the risk of graft loss and patient death [16].
Urinary Tract Infectionsare the most well-known infections necessitating hospitalization in renal allograft recipients, followed by pneumonias, postoperative infections and sepsis. Female recipients are at high risk of infection; other risk factors consist of deceased donors, recurrent Pre-transplant history of UTI, ureteric stents, prolonged catheterization, kidney-pancreas transplant with bladder drainage and intense immunosuppressive status [3,5,17].Escherichia coli appear to be the commonest culprit in such cases, however, unusual pathogens like Mycoplasma, tuberculosis, BK and JC viruses should be kept in mind [5].All UTIs involving renal allograft recipients are considered complicated, hence a standard antibiotic therapy should be given for 7–14 days.However, there is no international agreement for the management of asymptomatic bacteriuria,though randomized prospective trials suggested that treatment more than a year does not prevent symptoms to appear [18]. The current standard post-transplant prophylaxis consists of trimethoprim-sulfamethoxazole for 6-12 months post transplantation. Patients allergic to trimethoprim-sulfamethoxazole should be considered for an alternative prophylaxis [3].
Managing fungal
UTIs is a complicated issue in the transplant recipients and further attention
should be given to drug interactions between immunosuppressive medications and
antifungal therapy particularly CNI and mTOR inhibitors. Furthermore, radiological
imaging should be done to exclude the presence of fungus balls, abscesses, and
other urological anomalies that may demand surgical intervention or prolonged
therapy [3,5].
CNS Infection in transplanted individual is considered as an acute medical crisis. There are wide ranges of causative pathogens, including HSV, JC virus, listeria and C. neoformans.Once suspected, treatment should have started empirically as early as possible, while waiting other results, like blood culture, CSF analysis (including HSV-PCR and Cryptococcus-antigen) and imaging studies. Nevertheless, non-infections CNS causes needs to be considered, like lymphoma and calcineurin inhibitors toxicity[1].
6. Cytomegalovirus Infection
Cytomegalovirus canexhibiteither a direct intracellular affect in the transplant recipients, or might promptan invasive disease. Invasive disease commonly emerges amid first year following completing of prophylactic therapy and shown clinically as neutropenia,thrombocytopenia, fever, lymphadenopathy, chorioretinitis, meningoencephalitis, pneumonitis, gastro-intestinal signs (gastritis, ulcers, colitis and bleeding),hepatitis and pancreatitis. CMVcan occur in the transplanted recipients as a consequence of primary infection, re-activation, or viral super-infection.Primary infection or seroconversion, are the severe ones and occurs when sero-negative transplant recipients get the organ from sero-positive donor. Quantitative analytic tests are crucialin diagnosing and managing CMV disease. It consists of molecular-based analyses(PCR) and antigendetection.Negative tests do not exclude the diagnosis of active CMV infection.Presence of ulcers in the endoscopy is highly suggestive of the disease; in such cases PCR is an accurate technique for detection of CMV in the gastrointestinal mucosa even if PCR is negative in the blood[1,3,5,19].
Both
pre-emptive treatment and antiviral prophylaxis reducesthe risks of acquiring cytomegalovirus
disease.Furthermore, prophylactic therapy with antiviral can avoid different
viral infection likeHSV, EBV, human herpesvirus-6, herpesvirus-7 and varicella
zoster virus and reduces thecomplications of HCV and PTLD [20,21].Majority of centersofferprophylactic therapy intended
for the initial 3to6months post-transplant, withacyclovir, valacyclovir,
ganciclovir, valganciclovir andrarely, CMV hyper-immunoglobulin.Heart and lung
transplants will require prolong prophylaxis course.Nevertheless, recipients taking
valganciclovir or ganciclovir are at risks of myelosuppression, hence close
monitoring of blood counts is required.Ganciclovir resistance is rare, but it might
occur secondary to CMV UL54/or UL97 genes mutation. Cytomegalovirus syndrome and
invasive disease warrant therapy with intravenous ganciclovir, though recent data
analysis with the use of oral valganciclovir therapy ispromising[1,3,22].
Epstein–Barr Virusis responsible
mainly for PTLD, a specific group of lymphoproliferative diseases, with high
mortality rate of 40 to 60%, affecting mostlyrecipients with SOT[23].Risks for PTLD developmentconsist ofacquiring graft
from infectedEBV-seropositive donor in to EBV-seronegative recipient, other
risks include CMV co-infection, Anti-lymphocyte antiserum and allograft
rejection[23,24].Quantifiableviral-load assay,antigen
testsand histologic examinationthroughspecific EBV-RNA stainscan all assist in identification
and management of PTLD disease[24].In the
polyclonal type, reducing immunosuppressive medications alone might prompt disease
reversion;however, it may subject individuals to rejection. An aggressive illness
necessitatesalternate managements, including anti-CD20 antibodies, chemotherapy,
surgery and radiations (for CNS disease). T-cell immunotherapyarestill under on-going
trials and sirolimus emerges is an option against PTLD; however, additional
data are required to confirm its role as a protective agent[24-26].
BK-PolyomavirusesBK
virus has been linked to nephropathy and ureteral strictures in transplant
recipients. Diagnosis depends on identification of viral nucleic acids in serum
and urine. Unfortunately, there is no efficient antiviral treatment for polyoma-viruses;
however, diminishment in immunosuppressive medications might help in management.
Medications such cidofovir, leflunomide and intravenous immune globulin are
used widely; however, none of these drugs have been approved to be effective in
the treatment of polyomaviruses [1,3,27,28].
JC-Polyoma
virushas
been linked to progressive-multifocal leuko-encephalopathy. Similar to BK
virus, has no effective eradicative therapy (1,3).
6.1. Varicella
zoster infection
VZV has a prevalence of 3-10% in transplant populations and approximate mortality rate of 34% in patients with disseminated disease[28,29].It can manifest either as a primary disease (chickenpox or varicella) demonstrated clinically as vesicular eruptions on the head, trunk or extremities, or as a herpes zoster (shingles), manifested as a painful unilateral vesicular rashtaking a characteristic dermatomal shape, that might get disseminated leading to fatal outcomes.Time of onset is between 2 to 92 months post-solid organs transplant.Male gender, intensity of immunosuppression, escalation of immunosuppressant’s following acute rejection episode, MMF therapy, higher CNI level are altogether viewed as a risk factors for VZV infection[28,29]. Vaccination with live attenuated varicella vaccine ought to be prescribed to all sero-negative patients before transplantation, however, VZV vaccine ought to be avoided if transplant is expected within 4-6 weeks. Ganciclovir as CMV prophylaxis can protect against infection with VZV/HSV in the early post-transplant period[28,29].
Infected
patients should start oral acyclovir as earliest as possible to avert viral
dissemination in addition to reduction in MMF dosage.If A VZV-seronegative
transplant patient had exposed to an infected individual with varicella, then
he/she must receive varicella immune globulin within 96 hrs.fromcontact (if accessible).
If VZIG is not accessible, or the patient presented after 96 hours, then acyclovir
might be used as prophylactic therapy[28,29].
HCV replication might increase substantially in the immediate post-transplant period regardless to virus genotypes.Post-transplant HCV might manifest clinically astrivialrises of serum transaminasesthatrecoverwith lessening of immunosuppression.Approximately 20%–50% of affected individuals might have normal liver enzymes with unusual histological pictures;therefore,protocol liver biopsies every 6 to 12 months might be necessaryfor post-transplant assessment. Liver cirrhosis was estimated to be 5%-21% at 3 to7 years post-transplant.Acquirement of HCV disease post-transplantation has poor prognosis with rapidly progressive course[3,28,30]. Glomerular lesions depicted in renal transplant individuals incorporate cryoglobulinemia, non-cryoglobulinaemic membranoproliferative GN and membranous GN.HCVinfected recipients ought to be examined for proteinuria at regular intervals, and those detected to have new onset proteinuria must have kidney biopsy (3,30).Potential transplant candidate with HCV infection should be treated prior to transplantation based on liver histology.Interferon has variable successful rate (ranges from 20% to 90%) according to HCV genomes. Ribavirin should be avoided in advance kidney disease since it may induce acute haemolytic anaemia, whilethere is lackingevidence on the use of protease inhibitors in renal failure patients[3,30].
Post transplantation, HCV
infected recipients must be managed in consensus with herpetologist or
infectious disease specialists.Interferon therapy is not an option in
transplant recipients since it increases the risk of allograft rejection[1,2,28]. The ideal immunosuppressant’s in
HCV-infected kidney transplants is indefinite.Induction with OKT3 and
anti-thymocyte globulin has been linked to progressive liver disease.Tacrolimus
is associated with higher incidence of post-transplant diabetes mellitus as compared
tocyclosporine; additionally,these patients are prone to glomerulopathy with significant
proteinuria.Oppositely, sirolimus were found to reduce liver fibrosis in liver
transplant recipients [31], though this effect
is not prominent in renal transplant recipients with HCV.
Chronic HBV Patients with cleared viremia can be considered for transplant. However, theyrequireclose monitoring post-transplantation. Unfortunately, detection of HBV liver disease post-transplant can be challenging since liver enzymes levels may not precisely reflect the disease status.Sequential monitoring of HBV-DNA on periodic intervals (3 to 6months) is necessary and raised virus loads suggest imperviousness to treatment [3,28].Seven therapeutic selections are available and approved for management of chronic hepatitis B:IFNa, pegylated IFN, lamivudine, entecavir, telbivudine, tenofovir, and adefovir [3,28].IFN is not recommended in transplant recipient, and patients on Lamivudine can develop resistance to therapy, therefore KDIGO guidelines suggests usingtenofovir or entecavir which have a lower rate to drug resistance compared to lamivudine.
On the premise of current
information, it is suggested that antiviral therapy should started at the time of
transplants, regardless of HBV-DNA level, to overturn virus replication and avert
liver fibrosis [3]. Replication of the virus has
been associatedwith the net status of immunosuppression and not to any
individualdrugs; therefore, it is advisable to maintain HBV allograft
recipients on the lowest possible immunosuppressive dosage.
HBsAg-positive renalallograftreceiversought
to be screened for hepatocellular carcinoma with annual hepatic sonography
besides a-fetoprotein level measurements [3,28].
HIV was viewed in the past as a contraindication to transplantation;however, latest evidences propose that selected HIV candidates can have successful transplantation with acceptable survival rates, if they met the following criteria’s: the infection is well controlled with imperceptible viral loads and CD4 counts >200 cells/ml, and in the absence of active infections or malignancies [3,28]. It is desirable (if possible) to evade using protease inhibitors, for their known interactions with immunosuppressive drugs. However, the decision of anti-retroviral drugought to reflect HIV sensitivity results and to be agreed upon with the patient’sHIV physicians[3,28]. Monoclonal anti-IL2 receptor antibodies, for example daclizumab /basiliximab, have been appeared to raisethe CD4 levels, hence can be used as induction agents.Mycophenolate was found to reduce HIV replication in vitro while tacrolimus is desirable over cyclosporine as for reducing the rejection risk.HIV renal transplant patients should receive lifelong Pneumocystis prophylaxis with trimethoprim-sulfamethoxazole [3,28].
10. Human Herpes-virus 6, Human Herpes-virus 7
HHV-6 and HHV-7 belongs to Beta-herpesvirinae subfamily, genus
Roseolovirus. Viruses can remain dormant in the host tissues following primary
infection, and get reactivated in the presence of immunosuppressive therapy. Clinically
may manifests with fever, rash, myelosuppression, hepatitis, pneumonitis and
encephalitis.Moreover, HHV-7 may act as a co-factor for HHV-6 and CMV
reactivation, and both HHV-6 and HHV-7 may act as co-factors for the
pathogenesis of CMV disease and acute rejection[3,28].Viruses
can be detected through qualitative and quantitative molecular tests, by tissue
immunohistochemistry, and/or blood mononuclear cell culture.Treatment includesreduction
in immunosuppressive dosage besides ganciclovir therapy.Cidofovir and foscarnethave
additionally been used[3,28].
10.1. Human herpes-virus 8 (HHV 8)
belongs to Gammaherpesvirinae subfamily, and has been linkedto Kaposi’s
Sarcoma, primary effusive lymphoma, and Multicentric Castleman’s Disease
(lymphoproliferative disorder).Treatment for Kaposi’s Sarcoma incorporates immunosuppression
reduction and cytotoxic chemotherapy. Sirolimus can be used in such cases owed
to its antineoplastic characteristics besides being antirejection therapy [3,28].
10.2. Pneumonitis and Pneumocystis infection
it is less seen currently owing to the use of pneumocystis P. prophylaxis.Canmanifests clinically with dyspnea, severe hypoxemia, and cough that develop despite absence of clinical or radiological findings. There is no specific characteristic radiological pattern in the immunocompromised patients.Computed tomography is valuable in defining the extent of the disease and alsobronchoscopic examination for microbiological testing.Non-infectious cause’s needs to be considered in the differential diagnosis such as sirolimus induced pneumonitis[1,5].
10.3.
Mycobacterium tuberculosis
Tuberculosis incidence
is variable amongst kidney allograft recipients, contingent upon the endemicity
of the infection in their nations, while it ranges0.5%in North America it can
scopes to 15% in India and Pakistan with a mortality of 6.1% and allograft
survival rate of 97% at 1year.Tuberculosis usually
occurs at the initial 9 months post-transplant (0.5 to 13 months). Risk factors
for early tuberculosis include non-renal allograft, acute rejection, OKT3/anti-T
cell antibodies use and past exposure to M. tuberculosis [3,32,33].TB in immune-suppressed patients has
different clinical profile than in the normal populace.
Extra-pulmonary involvement and disseminated infection appears more
prominent in transplant population affecting nearly one third of the cases
compared to 15% of the normal individuals[3,5,32,33].
Tuberculosis in transplant recipients is suspected on clinical back ground.Neither tuberculin skin assessment norIFN-g release tests are appropriate for the determination of current infection. Occasionally, biopsy might be necessaryfor microbiological analysis. Management of active tuberculosis in transplant patients must consist offour-drug regime; isoniazid, rifampin, pyrazinamide, and ethambutol, all for the initial 2 months, followed withrifampin and isoniazid alone for the next four months.Extra-pulmonary involvements (bone, jointand CNS infection)may necessitatea longer period[3,5,32,33].Rifampincan activatesthe CYP3A4 pathway;therefore, it reducesCNI and mTOR inhibitors levels significantly, and aggravates rejection risk, hence frequent monitoring of dugs levels is recommended[35]. Rifampinmight be replacedin some patients with fluoroquinolones, however, it is necessary to do susceptibility analysis on all segregated mycobacterium bacilli to confirm the suitability of the chosen therapy.Role of Isoniazid as prophylactic therapy in transplant recipients is still arguable[34,35].
10.4. Chagas Disease
Chagas disease is a striking concern in North, Central and South America with 7.7 million people being tainted in 18 countries.People migrated from endemic zones had prompted significant increment in the number of infected populace in non-endemic places, which unfortunately had deferred the diagnosis and identification of Chagas disease due to lack of awareness and inexperience of health care providers in the required management resulting in appearance of fatal cases of Chagas disease post cardiactransplantation[36].Heart is theessential reservoir forT.cruzipathogens in infected patients; therefore, cardiac transplant from infected donors will prompt transmission of the disease and may cause recipient’s death, therefore utilization of cardiac allografts from infected seropositive donors is not advisable.Alternatively, non-cardiac allografts (such as liver and kidneys) mightbe considered and have reasonableoutcomes, however, T.cruzi-PCR monitoring should be done periodically and can detect disease re-activation before appearance of signs and symptoms [36].
Chagas cardiomyopathy is no more considered as relative contraindication to cardiac transplant, and grafts survivals is not inferiortocardiac-transplantation done for other reasons. Benznidazole is the treatment of choice for Chaga disease, other available agent is nifurtimox, though both does not cure chronic T.cruzipathogens.Other medication noted to have antitrypanosomal activities are posaconazole and allopurinol, but they are under on-going clinical trials [36]. Myocarditis secondary to Chaga reactivation could be misdiagnosed as allograft rejection which if managed with increased immunosuppression can prompt extensive dissemination, cardiac biopsy with histopathological examination might be necessary in such cases and can detect intracellular T.cruzi-amastigotes; moreover, it will identify the degree of fibrosis, tissue necrosis, position and the extent of cellular infiltrate. Considering the high risk of Chaga disease reactivation, severalcentershad recommended prophylactic anti-trypanosomal therapy in allcardiac transplant patients [36].
11. Distinction between acute Rejection and Infectious Complications
In majority of transplant cases,
infection is easily distinguishable from rejectionbasedon clinical data, timing
of infection, patient signs and symptoms and laboratory tests.Moreover,
cultures, viral loads, imaging, Procalcitonin
(particularly in lung transplant recipients), Acute Phase Proteins (APPs) such
as C-Reactive Protein (CRP) or Serum-Amyloid A (SAA), ImmuKnow assays, all have
demonstrated some role in differentiating infection from rejection episodes,
however, their roles are still questionable and in some cases allograft infection may bear a
resemblance to rejection. In such cases allograft biopsy with clinic-pathological
correlation might be
necessary to distinguish these two entities.Recognition of tissue
deposition of complements parts (particularly C4d) by IHC/ IF is the basic
component of indicative
criteria for ABMR. Furthermore, antigens detection to infectious organisms in
allograft biopsy specimens has a pivotal role in the accurate diagnosis and proper therapy for
tissue-invasive infection in transplant patients [1,37-41].
11.1.
Commonest
Infections Among Transplant Travellers and Preventive Measures
11.2. Traveller's Diarrhoea
Diarrhoea is a common among travellers to developing countries (affecting 10-60%), and it might be life-threatening to immune-compromised patients.Prior to travel, organ recipients must be educated in appropriate food and water precautions.They should be warned to drink boiled or bottled water and other beverages and to avoid direct drinking of water from wells and lakes (as it might be contaminated with cryptosporidium or giardia), and avoid food sold by street sellers and raw foods (except fruit and vegetables that can be peeled) and unpasteurized dairy products (as it might be contaminated with Listeria or E. coli). Moreover, Immune-compromised travellers must carry some antimicrobial drugs for possibleuse in acute emergencies.Fluoroquinolones are the ideal choice for empirical usage in case of travellers’ diarrhoea (alternatively, azithromycin can be given, but with caution if patients taking cyclosporine/ Tacrolimus, hence the drug level might be transiently increased)[1-4,42-44].Transplant recipients with severe refractory diarrhoea, particularly if accompanied with fever, vomiting and/or bloody stools, must seeks medical physician.
11.3. Respiratory Infections
Respiratory diseases are the second common infection influencing travellers.All
transplant recipients ought to get pneumococcal vaccines and annual influenza vaccination.Transplant
recipients are at greater risk for invasive fungal infection, and ought to
dodge activities,for example, spelunking and excavating, exercises that have
been related toCryptococcus neoformans or
endemic fungi[1,42].
11.4. Malaria and Other Arthropod-Borne Disease
Malaria and
dengue fever are the most common arthropod borne disease among travellers.Malaria
prophylaxis should be given based on traveller’sdestinations. Choloroquineis
the first-line Malaria prophylactic agent for individuals traveling to endemic areas
with chloroquine-sensitive malaria, however, it might increase cyclosporine
levels, and therefore periodic cyclosporine monitoring is needed. On the other
hand, transplant travellers to areas endemic for choloroquine-resistant
malaria, three main prophylactic options are present: atovaquone/proguanil,
mefloquine and doxycycline[42-44].Prophylactic
medications ought to be begun few weeks preceding travel to allow
immunosuppressant’s level monitoring prior to travel and to be rechecked again after
returning from journey and stopping prophylaxis. In addition to malarial chemoprophylaxis,
transplant recipients should be advised on approaches that can limit insect
bites, such as evading mosquitos, particularly during dusk and dawn when
mosquitoes that transmit malaria are most likely to biteand to use insect’srepellents,
protective wears and bed nets. Such protection will also reduce other insect
borne illnesses (e.g. Chikungunya) [42-44].
11.5. Sun Exposure and Skin Exposure
It is advisable for transplant travellers to have protective measures such as wearing sunglasses, caps, protective clothing and applying sunblockers creams to minimise sun rays concentration and exposure and avoid walking barefoot or swimming in freshwater, which can put them at increased risk for abrasions, infections, and parasitic disease[44-46].
11.6.
Sexually Transmitted Diseases
Vaccination is
generally less effective in the presence of immunosuppression and has limited
immunological protection period.Moreover, live vaccines are contraindicated
post-transplantation, since it might lead to disseminated infection in
immune-compromised patients. Hence the need for vaccination ought to be
assessed before transplantation. Examples of these vaccines are influenza (live
attenuated), Measles, Mumps, Rubella (MMR), varicella, rota virus, activated poliomyelitis
vaccine and BCG.Immune globulins should be considered for susceptible individuals
travelling to endemic areas.A minimum of 4 weeks between live-virus vaccine
administration and transplantation is suggested[1,3,42-45].On
the other hand, Pneumococcal vaccination is suggested each 3-5 year, while influenza
immunization is suggested yearly.Additional vaccinations are prescribed
accordingly to patients traveling to endemic areas where certain diseases are
present [1,3].
12. Travel Vaccines
When
possible, vaccination for travel should be started several months before the
trip, to allow time for possible additional boosters and serologic evaluations.
Hepatitis Bvaccine might be suggested
for certain transplant patients,
incorporatingthose with new sexual partners while
traveling, and those going to live in endemic countries.
12.1. Hepatitis A vaccines
Hepatitis A vaccine is less efficient in transplant patients. However,
if the trip planned in advance with sufficient time before travel, and the
transplant recipients are no less than a year post-transplant and on modest
immunosuppressive dosage, then it might be valuable to be vaccinated with two vaccine
doses of 6-12 months separated. Conversely, if the transplant individual does
not have enough time, then ought to be given intramuscular immunoglobulin
before travelling.Immunoglobulin’scan provide 85 to 90% protective effect;
however, such effects can persistonly for 3-6 months[42-45].
12.2. Tetanus, Diphtheria and Pertussis
Though tetanus is rare among travellers, however, all adults including SOT recipients should have a tetanus booster dose before traveling.Diphtheria is common in poor areas with 5–10% mortality among normal hosts, despite therapy. Patients vaccinated more than 10 years before travel should be revaccinated before entering an area in which diphtheria is endemic or resurgent. The incidence of pertussis has been increasing worldwide over the last 20 years; as 90% of pertussis still occurs in developing countries, it is important to ensure that all travellers including SOT recipients are protected. A newer a cellular adult vaccine for pertussis is available, in combination with tetanus and diphtheria (Tdap). Although administration of Tdap has not specifically been studied in SOT recipients, given the risk and consequences of developing pertussis in travellers, a single dose of Tdap should be given to adult travellers who have not recently received Tdap[42-45].
12.2.1. Typhoid Fever: Immune-compromised patients are at great risk of developing severe complications with typhoid infection; hence they must be vaccinated prior to travelling to endemic places. There are 2 available vaccines for typhoid fever; TyphimVi® (Aventis Pasteur SA), which is a polysaccharide inactivated vaccine, and Vivotif®which an oral attenuated live vaccine. The live attenuated oral typhoid vaccine should be avoided in immune-compromised patients.
12.2.2.
Meningococcal
disease:is associated with
high mortality rate. The meningococcal immunization is a quadrivalent
polysaccharide (against N.meningitidis A, C,
Y, W-135), and indicated for people going by territories with a flare-up of
intrusive meningococcal disease brought on by a sero- group incorporated into
the vaccine. Confirmation of vaccination is compulsory for Muslim travellers to
Saudi Arabia for hajj or umra. The
vaccine effects tend to
decline over the initial 6-12 months following vaccination and revaccination might
be required for a new travel[42,43].
13.
Rabies
Rabies vaccine is an injectable inactivated virus. Only individuals expecting intense animal exposure, and thoseon long-term (≥30 days) travel and plans to be far from medical careshould receive rabies vaccine. All travellers with a potential rabies exposure should receive post-exposure prophylaxis, starting with immediate cleansing of the wound with soap and water. Those who have not previously been immunized should receive multiple doses of intramuscular vaccine, plus rabies immune globulin (HRIG) (20 units/kg), half at the site and half intramuscular. Those who have received pre-exposure prophylaxis receive two more doses on days 0 and 3 and no HRIG. Since SOT recipients may not mount adequate antibody responses to the rabies vaccine (titers>0.5 IU/mL are considered adequate), some recommend administration of HRIG followinganimal’sexposure [42-46].
13.1. Yellow fever
Yellow fever vaccine is a live attenuated virus and must not be given to solid organ recipients. Ideally transplant recipients must avoid countries where the yellow fever is endemic.
13.2. Japanese encephalitis
JE vaccine is a killed viral vaccine with high efficacy of80 to 90%. Vaccination against JE should be considered for travellers to areas of Asia endemic with JE[42-45].
13.3. BacilleCalmette-Guerin and tuberculosis
BacilleCalmette-Guerin
(BCG) is a live, attenuatedstrain of M. bovis,
and is used to prevent tuberculosis,especially in infants and children,
however, BCG is contraindicated in SOTrecipients because they can develop
disseminated BCG.There are no specific approaches to prophylaxis other
thanwearing appropriate masks in health care settings in endemicregions[44].
14. Conclusions
·
Any acute and active infection affecting
transplant recipients must be eliminated prior to transplant surgery.
·
Advanced and sensitive techniques such
as immunoassays, microbiological assays and others, may permit titration of
immunosuppression, hence decreasingmortalityrate from infection and malignancy,
however, these techniques are still under development.
·
Routine post-surgical antimicrobial
prophylaxis depends on the organ transplanted and local epidemic organisms, and
has to be adjusted based on cultured colonized organisms.
Figure 2: Diagrammatic
illustration for PTLD management.
1.
FishmanJA (2007) Infection in Solid-Organ Transplant Recipients. N Engl J
Med 357:2601-2614.
2. Dixon
B Kaufman, VecihiBatuman (2015)Assessment and Management of the Renal
Transplant Patient. Medscape2015.
4. OsemwegieEmovon,
G. Mark Baillie PR, Rajagopalan, Kenneth Chavin (2017).Infections after Kidney
Transplantation. Medscape Transplantation 2017.
5.
Patricia Muñoz, Nina Singh,Emilio Bouza (2017)Fever
in Organ Transplant. Recipients.
38. McGovern
PC and Blumberg EA (2001)Differentiation between infection and rejection in the
management of cardiac transplant patients. Curr Infect Dis Rep 3: 328.